On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
How can DAOs - Decentralized Autonomous Organizations - improve rare disease research? Biorasi's Few & Far Between Podcast welcomes Dr. Jocelynn Pearl, Senior Scientist...
"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will...
"We work with hundreds of patients a month, helping them understand their own medical history and then tracking what happens to them in the...